T. Brender

Most-cited papers

1. Interleukin 20: discovery, receptor identification, and role in epidermal function.

   H. Blumberg, D. Conklin, Wen-Feng Xu, A. Grossmann +22 more

   2001Cell586 citations Open access

   Semantic Scholar

   Save

2. Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F

   R. Kuestner, David W. Taft, Aaron C. Haran, C. Brandt +24 more

   2007Journal of Immunology368 citations Open access

   Semantic Scholar

   Save

3. Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes

   J. Parrish-Novak, Wen-Feng Xu, T. Brender, Lena Yao +9 more

   2002Journal of Biological Chemistry288 citations Open access

   Semantic Scholar

   Save

4. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist

   Wen-Feng Xu, Scott R. Presnell, J. Parrish-Novak, W. Kindsvogel +19 more

   2001Proceedings of the National Academy of Sciences of the United States of America225 citations Open access

   Semantic Scholar

   Save

5. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

   K. Hippen, C. Bucher, Dawn K. Schirm, A. Bearl +10 more

   2012Blood86 citations Open access

   Semantic Scholar

   Save

6. Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis

   Jing Li, Hui Wei, S. Krystek, D. Bond +18 more

   2017Analytical Chemistry76 citations Open access

   Semantic Scholar

   Save

7. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

   R. Mabry, K. Lewis, M. Moore, P. Mckernan +30 more

   2009Protein engineering, design & selection : PEDS56 citations

   Semantic Scholar

   Save

8. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

   Natalie A. Bezman, Amy Jhatakia, Alper Y. Kearney, T. Brender +8 more

   2017Blood Advances45 citations Open access

   Semantic Scholar

   Save

9. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist.

   Heather E. Metz, M. Childs, Jamie Brevik, D. Winship +14 more

   202024 citations

   Semantic Scholar

   Save

10. Abstract 3271: A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors

    K. Moyes, T. Brender, S. Smith, Heng-Yu Xu +8 more

    2019Immunology12 citations

    Semantic Scholar

    Save

11. Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTAC™therapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity

    M. Comeau, T. Brender, M. Childs, Jamie Brevik +14 more

    2020Immunology6 citations

    Semantic Scholar

    Save

12. Abstract PD4-09: Preclinical studies support the development of SBT6050, an anti-HER2 antibody conjugated to a potent TLR8 agonist, for treatment of moderate and high HER2-expressing tumors that lack pre-existing T cell infiltrate

    V. Odegard, K. Moyes, M. Childs, Jamie Brevik +13 more

    2020Poster Spotlight Session Abstracts1 citations

    Semantic Scholar

    Save

13. Meeting Overview: Plenary and Workshop Sessions

    C. Biron, S. Gordon, E. Mocarski, A. Sher +496 more

    20020 citations

    Semantic Scholar

    Save